The combination of dabrafenib plus trametinib represents standard of care for BRAF-V600E-mutant melanoma and lung cancer patients (Long et al. 2015; Planchard et al. 2017) and was applied in case of BRAF-V600E mutation on the basis of several case reports in brain tumors (Johanns et al. 2018). This evidence concerns the gene BRAF and lung cancer.